Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.
Hideko YamauchiMasakazu ToiShin TakayamaSeigo NakamuraToshimi TakanoKaren CuiChristine CampbellLiesbet De VosCharles GeyerAndrew TuttPublished in: Breast cancer (Tokyo, Japan) (2023)